Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Trial Profile

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 10 Apr 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 12 Dec 2017 Results (n=13) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top